Pharmion licenses cancer candidate from MethylGene
Pharmion (oncology and hematology therapeutics) has licensed from fellow cancer drug developer MethylGene research, development, and commercialization rights to histone deacetylase (HDAC) inhibitors, including MethylGene's Phase I MGCD0103 for solid tumors and blood cancers as well as the company's pipeline of second-generation HDAC inhibitors for cancer indications.
- Specialty Pharmaceuticals
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com